{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T11:43:00Z","timestamp":1786189380523,"version":"build-2736575974"},"posted":{"date-parts":[[2026,8,6]]},"group-title":"Gastroenterology","reference-count":35,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.medrxiv.org\/about\/FAQ#license"}],"funder":[{"award":["R01-CA160254-11"],"award-info":[{"award-number":["R01-CA160254-11"]}],"id":[{"id":"https:\/\/ror.org\/040gcmg81","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,8,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                <jats:p>Hepatocellular Carcinoma (HCC) arising from Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is an increasing public health burden with high mortality, highlighting the need for improved early detection strategies. Current surveillance tools, including Alpha-fetoprotein (AFP) and ultrasound, lack sufficient sensitivity for early-stage HCC detection. We analyzed serum samples from 131 patients, including 58 with cirrhosis and 73 with MASLD-related HCC (42 early-stage, 31 late-stage), using an nLC-stepped HCD-PRM-MS\/MS workflow for targeted N-glycome profiling of glycopeptides derived from haptoglobin and vitronectin. Combining targeted glycopeptides with AFP significantly improved HCC detection compared with AFP alone. The optimal panel for all HCC versus cirrhosis (AFP + VTNC_169_A2G2F0S1 + VTNC_242_A3G3F2S2) achieved an AUC of 0.859 and 76.7% sensitivity at 90% specificity. For early-stage HCC, AFP + HP_184_A3G3F1S3 + VTNC_169_A2G2F0S1 yielded an AUC of 0.890 with 66.7% sensitivity at 1% specificity. A SHAP-selected Gaussian Naive Bayes model based on seven molecular\/glycopeptide features, without demographic variables, further improved performance, achieving ROC-AUC values of 0.9985 in training and 1.0000 in independent testing cohorts, with accuracies of 98.1% and 100.0%, respectively.<\/jats:p>\n                <jats:sec>\n                  <jats:title>GRAPHICAL ABSTRACT<\/jats:title>\n                  <jats:fig id=\"ufig1\" position=\"float\" orientation=\"portrait\" fig-type=\"figure\">\n                    <jats:graphic xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"26359485v1_ufig1\" position=\"float\" orientation=\"portrait\"\/>\n                  <\/jats:fig>\n                <\/jats:sec>","DOI":"10.64898\/2026.08.04.26359485","type":"posted-content","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T19:40:11Z","timestamp":1786045211000},"source":"Crossref","is-referenced-by-count":0,"title":["Predicting Early MASLD-HCC from Serum N-Glycomics: A SHAP-Interpreted Gaussian Naive Bayes Model Built on nLC-HCD-PRM-MS\/MS Profiling"],"prefix":"10.64898","author":[{"given":"Yu","family":"Lin","sequence":"first","affiliation":[{"name":"Department of Surgery, University of Michigan Medical Center, Ann Arbor, Michigan 48109, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1751-4361","authenticated-orcid":false,"given":"Chithravel","family":"Vadivalagan","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Michigan Medical Center, Ann Arbor, Michigan 48109, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianliang","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suyu","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natan Y.","family":"Lubman","sequence":"additional","affiliation":[{"name":"Institute for Interdisciplinary Computational Science, Stein Faculty of Computer and Information Science, Ben-Gurion University of the Negev"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Lubman","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Michigan Medical Center, Ann Arbor, Michigan 48109, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2026080803550920000_2026.08.04.26359485v1.1","doi-asserted-by":"crossref","unstructured":"Huang, M. ; Chen, H. ; Wang, H. ; Wang, X. ; Wang, D. ; Li, Y. ; Zhou, Q. ; Zhang, D. ; Li, M. ; Ma, L . Worldwide burden of liver cancer due to metabolic dysfunction-associated steatohepatitis from 1990 to 2019: insights from the Global Burden of Disease study. Frontiers in Oncology 2024, 14, 1424155.","DOI":"10.3389\/fonc.2024.1424155"},{"issue":"1","key":"2026080803550920000_2026.08.04.26359485v1.2","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s12986-025-01000-4","article-title":"Prevalence and risk of metabolic dysfunction-associated steatotic liver disease in patients with sarcopenic obesity: a systematic review and meta-analysis","volume":"22","year":"2025","journal-title":"Nutrition & Metabolism"},{"issue":"1","key":"2026080803550920000_2026.08.04.26359485v1.3","doi-asserted-by":"crossref","first-page":"e2454707","DOI":"10.1001\/jamanetworkopen.2024.54707","article-title":"Estimated Burden of Metabolic Dysfunction\u2013Associated Steatotic Liver Disease in US Adults, 2020 to 2050","volume":"8","year":"2025","journal-title":"JAMA Network Open"},{"key":"2026080803550920000_2026.08.04.26359485v1.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.01.023"},{"key":"2026080803550920000_2026.08.04.26359485v1.5","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.10.031"},{"key":"2026080803550920000_2026.08.04.26359485v1.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2014.11.002"},{"issue":"7","key":"2026080803550920000_2026.08.04.26359485v1.7","doi-asserted-by":"crossref","first-page":"545","DOI":"10.2217\/bmm-2018-0414","article-title":"Clinical performance of \u03b1-L-fucosidase for early detection of hepatocellular carcinoma","volume":"13","year":"2019","journal-title":"Biomarkers in medicine"},{"issue":"1","key":"2026080803550920000_2026.08.04.26359485v1.8","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1471-2407-12-17","article-title":"Golgi protein 73 versus alpha-fetoprotein as a biomarker for hepatocellular carcinoma: a diagnostic meta-analysis","volume":"12","year":"2012","journal-title":"BMC cancer"},{"key":"2026080803550920000_2026.08.04.26359485v1.9","doi-asserted-by":"publisher","DOI":"10.1021\/pr4011519"},{"issue":"12","key":"2026080803550920000_2026.08.04.26359485v1.10","doi-asserted-by":"crossref","first-page":"6079","DOI":"10.1021\/acs.jproteome.5c00626","article-title":"Integrative Analysis of Fucosylated Tetra Glycoforms in Hepatocellular Carcinoma: A NanoLC-PRM-MS\/MS and Machine Learning Approach","volume":"24","year":"2025","journal-title":"Journal of proteome research"},{"issue":"8","key":"2026080803550920000_2026.08.04.26359485v1.11","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.3390\/biomedicines13082034","article-title":"Glycomics in Human Diseases and Its Emerging Role in Biomarker Discovery","volume":"13","year":"2025","journal-title":"Biomedicines"},{"issue":"1","key":"2026080803550920000_2026.08.04.26359485v1.12","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/s41392-024-01886-1","article-title":"Glycosylation: mechanisms, biological functions and clinical implications","volume":"9","year":"2024","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"2026080803550920000_2026.08.04.26359485v1.13","doi-asserted-by":"crossref","unstructured":"Abrantes, R. ; Lopes, J. ; Lopes, D. ; Gomes, J. ; Melo, S. A. ; Reis, C. A . Sialyl-Tn glycan epitope as a target for pancreatic cancer therapies. Frontiers in Oncology 2024, 14, 1466255.","DOI":"10.3389\/fonc.2024.1466255"},{"key":"2026080803550920000_2026.08.04.26359485v1.14","doi-asserted-by":"crossref","unstructured":"Freitag, A. ; Khilji, S. K. ; Nedielkov, R. ; Kumar, S. M. ; Krummhaar, M. ; Arndt, J. ; Garcia Moreira, G. M. S. ; Luhle, J. ; Goerdeler, F. ; Kamphues, C . An Integrative Approach to Develop and Characterise Antibodies Against the Cancer Associated Antigen Sialyl Lewis A (CA 19-9). bioRxiv 2025, 2025.2006. 2015.659274.","DOI":"10.1101\/2025.06.15.659274"},{"key":"2026080803550920000_2026.08.04.26359485v1.15","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.231191"},{"issue":"26","key":"2026080803550920000_2026.08.04.26359485v1.16","doi-asserted-by":"crossref","first-page":"22850","DOI":"10.1021\/acsomega.2c02600","article-title":"Glycopeptides with Sialyl Lewis antigen in serum haptoglobin as candidate biomarkers for nonalcoholic steatohepatitis hepatocellular carcinoma using a higher-energy collision-induced dissociation parallel reaction monitoring-mass spectrometry method","volume":"7","year":"2022","journal-title":"ACS omega"},{"issue":"21","key":"2026080803550920000_2026.08.04.26359485v1.17","doi-asserted-by":"crossref","first-page":"5273","DOI":"10.3390\/cancers13215273","article-title":"The cancer-associated antigens Sialyl Lewisa\/x and Sda: Two opposite faces of terminal glycosylation","volume":"13","year":"2021","journal-title":"Cancers"},{"issue":"3","key":"2026080803550920000_2026.08.04.26359485v1.18","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.apsb.2023.10.014","article-title":"The role of N-glycosylation in cancer","volume":"14","year":"2024","journal-title":"Acta Pharmaceutica Sinica B"},{"key":"2026080803550920000_2026.08.04.26359485v1.19","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/bs.acr.2022.07.005","article-title":"Mass spectrometry based biomarkers for early detection of HCC using a glycoproteomic approach","volume":"157","year":"2023","journal-title":"Advances in Cancer research"},{"issue":"4","key":"2026080803550920000_2026.08.04.26359485v1.20","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1515\/cclm-2018-0379","article-title":"Aberrant glycosylation and cancer biomarker discovery: a promising and thorny journey","volume":"57","year":"2019","journal-title":"Clinical Chemistry and Laboratory Medicine (CCLM"},{"issue":"5","key":"2026080803550920000_2026.08.04.26359485v1.21","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1074\/mcp.M112.023259","article-title":"Site-specific glycoforms of haptoglobin in liver cirrhosis and hepatocellular carcinoma","volume":"12","year":"2013","journal-title":"Molecular & Cellular Proteomics"},{"key":"2026080803550920000_2026.08.04.26359485v1.22","doi-asserted-by":"publisher","DOI":"10.1002\/mas.21583"},{"issue":"13","key":"2026080803550920000_2026.08.04.26359485v1.23","doi-asserted-by":"crossref","first-page":"12467","DOI":"10.1021\/acsomega.3c00519","article-title":"Discovery of core-fucosylated glycopeptides as diagnostic biomarkers for early HCC in patients with NASH cirrhosis using LC-HCD-PRM-MS\/MS","volume":"8","year":"2023","journal-title":"ACS omega"},{"issue":"14","key":"2026080803550920000_2026.08.04.26359485v1.24","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1007\/s00216-019-01775-5","article-title":"Parallel reaction monitoring with multiplex immunoprecipitation of N-glycoproteins in human serum for detection of hepatocellular carcinoma","volume":"411","year":"2019","journal-title":"Analytical and bioanalytical chemistry"},{"issue":"5","key":"2026080803550920000_2026.08.04.26359485v1.25","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1074\/mcp.M112.023325","article-title":"Quantitative liquid chromatography-mass spectrometry-multiple reaction monitoring (LC-MS-MRM) analysis of site-specific glycoforms of haptoglobin in liver disease","volume":"12","year":"2013","journal-title":"Molecular & Cellular Proteomics"},{"issue":"7","key":"2026080803550920000_2026.08.04.26359485v1.26","doi-asserted-by":"crossref","first-page":"3590","DOI":"10.1021\/acs.jproteome.1c00162","article-title":"Development of parallel reaction monitoring assays for the detection of aggressive prostate cancer using urinary glycoproteins","volume":"20","year":"2021","journal-title":"Journal of proteome research"},{"issue":"6","key":"2026080803550920000_2026.08.04.26359485v1.27","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1021\/acs.jproteome.1c00175","article-title":"A panel of glycopeptides as candidate biomarkers for early diagnosis of NASH hepatocellular carcinoma using a stepped HCD method and PRM evaluation","volume":"20","year":"2021","journal-title":"Journal of proteome research"},{"issue":"7","key":"2026080803550920000_2026.08.04.26359485v1.28","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s13205-026-04901-0","article-title":"Unveiling the role of glycoproteins in hepatocellular carcinoma: from biomarkers to therapeutic interventions","volume":"16","year":"2026","journal-title":"3 Biotech"},{"key":"2026080803550920000_2026.08.04.26359485v1.29","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jproteome.0c00270"},{"issue":"6","key":"2026080803550920000_2026.08.04.26359485v1.30","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1021\/acs.jproteome.1c00175","article-title":"A panel of glycopeptides as candidate biomarkers for early diagnosis of NASH hepatocellular carcinoma using a stepped HCD method and PRM evaluation","volume":"20","year":"2021","journal-title":"Journal of proteome research"},{"issue":"12","key":"2026080803550920000_2026.08.04.26359485v1.31","doi-asserted-by":"crossref","first-page":"8201","DOI":"10.1021\/acs.analchem.0c00420","article-title":"Quantitative analysis of \u03b1-1-antitrypsin glycosylation isoforms in HCC patients using LC-HCD-PRM-MS","volume":"92","year":"2020","journal-title":"Analytical chemistry"},{"key":"2026080803550920000_2026.08.04.26359485v1.32","doi-asserted-by":"crossref","unstructured":"Bezstarosti, K. ; Van der Wal, L. ; Doff, W. A. ; Demmers, J. A . Parallel reaction monitoring targeted mass spectrometry as a fast and sensitive alternative to antibody-based protein detection. Frontiers in Analytical Science 2024, 4, 1397810.","DOI":"10.3389\/frans.2024.1397810"},{"issue":"8","key":"2026080803550920000_2026.08.04.26359485v1.33","doi-asserted-by":"crossref","first-page":"563","DOI":"10.3390\/metabo11080563","article-title":"PRM-MS quantitative analysis of isomeric N-glycopeptides derived from human serum haptoglobin of patients with cirrhosis and hepatocellular carcinoma","volume":"11","year":"2021","journal-title":"Metabolites"},{"issue":"3","key":"2026080803550920000_2026.08.04.26359485v1.34","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.cgh.2019.11.012","article-title":"GALAD score detects early hepatocellular carcinoma in an international cohort of patients with nonalcoholic steatohepatitis","volume":"18","year":"2020","journal-title":"Clinical gastroenterology and hepatology"},{"key":"2026080803550920000_2026.08.04.26359485v1.35","doi-asserted-by":"crossref","first-page":"1213898","DOI":"10.3389\/fonc.2023.1213898","article-title":"Discovery of a haptoglobin glycopeptides biomarker panel for early diagnosis of hepatocellular carcinoma","volume":"13","year":"2023","journal-title":"Frontiers in Oncology"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.64898\/2026.08.04.26359485","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T10:55:22Z","timestamp":1786186522000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.64898\/2026.08.04.26359485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":35,"URL":"https:\/\/doi.org\/10.64898\/2026.08.04.26359485","relation":{},"subject":[],"published":{"date-parts":[[2026,8,6]]},"subtype":"preprint"}}